Sling vs Botox for Mixed Incontinence (MUSA)
Urinary Incontinence, Stress, Urinary Incontinence, Urge
About this trial
This is an interventional treatment trial for Urinary Incontinence, Stress focused on measuring urinary incontinence, midurethral sling, Botulinum toxin A (Botox A ®)
Eligibility Criteria
Inclusion Criteria:
Reporting at least "moderate bother" from UUI item on UDI
* "Do you experience urine leakage associated with a feeling of urgency?"
Reporting at least "moderate bother" from SUI item on UDI
* "Do you experience urine leakage related to physical activity, coughing, or sneezing?"
- Diagnosis of SUI defined by a positive cough stress test (CST) or UDE within the past 18 months
- Presence of UUI on bladder diary with > 4 Urgency IE/3-day diary
- Urinary symptoms >3 months
- Persistent symptoms despite at least one or more conservative treatments (e.g. supervised behavioral therapy, physical therapy) as determined adequate by the physician.
Inadequate response to oral overactive bladder medications (including anti-cholinergic and/or beta-mimetic medication) unless patient is
- intolerant of oral overactive bladder medications, or
- oral overactive bladder medications are contraindicated as determined by the treating provider.
- Urodynamics within past 18 months
- Demonstrates ability (or have caregiver demonstrate ability) to perform clean intermittent self-catheterization.
Exclusion Criteria:
Anterior or apical compartment prolapse at or beyond the hymen (>0 on POPQ), regardless if patient is symptomatic
* Women with anterior or apical prolapse above the hymen (<0) who do not report vaginal bulge symptoms will be eligible
Planned concomitant surgery for anterior vaginal wall or apical prolapse > 0
* Women undergoing only rectocele repair or other repair unrelated to anterior or apical compartment are eligible
- Women undergoing hysterectomy for any indication will be excluded
- Active pelvic organ malignancy
- Age <21 years
- Pregnant or plans for future pregnancy in next 6 months, or within 12 months post-partum
- Post-void residual >150 cc on 2 occasions within the past 6 months, or current catheter use
- Participation in other trial that may influence results of this study
- Unevaluated hematuria
- Prior sling, synthetic mesh for prolapse, implanted nerve stimulator for urinary incontinence
- Spinal cord injury or advanced/severe neurologic conditions including Multiple Sclerosis, Parkinsons, Myasthenia Gravis, Charcot-Marie-Tooth
- Women on overactive bladder medication/therapy will be eligible after 3 week wash-out period
- Non-ambulatory
- History of serious adverse reaction to synthetic mesh
- Not able to complete study assessments per clinician judgment, or not available for 6 month follow-up
- Diagnosis of and/or history of bladder pain or chronic pelvic pain
- Women who had intravesical Botox injection within the past 12 months
- Women who have undergone anterior or apical pelvic organ prolapse repair within the past 6 months
Sites / Locations
- University of Alabama at Birmingham, Department of Obstetrics and Gynecology
- University of California at San Diego
- Kaiser Permanente
- Duke University, Duke Division of Urogynecology and Reconstructive Pelvic Surgery
- University of Pennsylvania
- Magee-Women's Hospital, Department of Obstetrics and Gynecology
- Brown/ Women and Infants Hospital of Rhode Island, Center for Women's Pelvic Medicine and Reconstructive Surgery
- University of Texas Southwestern Medical Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Botox A® injection
Mid-urethral sling
A dose of 100 units of Botulinum toxin A will be injected into the bladder. Follow up visits at 2 weeks, 3 and 6 months post intervention to collect clinical and patient-reported outcomes.
Mid-urethral Sling Procedure includes retropubic as well as transobturator full length slings. Follow up visits at 2 weeks, 3 and 6 months post intervention to collect clinical and patient-reported outcomes.